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Sleep Disturbances in Adults with Eczema Are
Associated with Impaired Overall Health: A US
Population-Based Study
Jonathan I. Silverberg1, Nitin K. Garg2, Amy S. Paller3, Anna B. Fishbein4 and Phyllis C. Zee5
Sleep disturbances are associated with poor health outcomes in adults. However, little is known about the sleep
disturbances that occur in adult eczema. We studied the association between adult eczema and sleep
disturbance and their impact on overall health and health care utilization. We used the 2012 National Health
Interview Survey, a cross-sectional questionnaire of 34,613 adults. Eczema was associated with higher odds of
fatigue (odds ratio (95% confidence interval): 2.97 (2.65–3.34)), regular daytime sleepiness (2.66 (2.34–3.01)), and
regular insomnia (2.36 (2.11–2.64)), even after controlling for sleep duration, history of allergic disease,
sociodemographics, and body mass index. There were significant interactions between eczema and fatigue,
sleepiness, and insomnia as predictors of poorer overall health status, number of sick days, and doctor visits,
such that eczema and each of the sleep symptoms were associated with higher odds of poorer outcomes than
either eczema or sleep symptoms alone. Latent class analysis was used and identified five classes of fatigue, sleep
disturbances, and allergic disorders. Two classes had high probabilities of eczema: one with high probabilities of
asthma, hay fever, food allergy, and multiple sleep symptoms and the other with intermediate probability of
insomnia alone. Future studies are warranted to better characterize sleep loss in eczema and develop strategies
for treatment and prevention.
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INTRODUCTION
Sleep disorders are associated with poor performance in school
and work, impaired overall health and safety, and con-
siderable economic burden (Skaer and Sclar, 2010). Eczema
is a common inflammatory skin condition that causes signi-
ficant morbidity secondary to severe itch, sleep impairment,
social embarrassment, and psychological distress (Carroll et al.,
2005). Sleep disturbance is attributed to the intense pruritus; it
results in functional impairment (daytime fatigue, irritability,
disturbed cognition, and decreased motor performance) and
profoundly worsens the quality of life (QOL) in eczema patients
(Bender et al., 2003; Beattie and Lewis-Jones, 2006; Ricci et al.,
2007; Beikert et al., 2014). Having eczema and concurrent
sleep disturbance also significantly increases the risk of
psychological disorders (Romanos et al., 2010; Schmitt et al.,
2011), motor vehicle accidents, and workplace injury (Young
et al., 1997; Akerstedt et al., 2002; Gander et al., 2005).
Previous studies have demonstrated significantly worsened
sleep quality in childhood eczema with less sleep, more
frequent and prolonged awakening, and overall lower sleep
efficiency (Monti et al., 1989; Dahl et al., 1995; Stores et al.,
1998; Chamlin et al., 2005; Hon et al., 2008; Camfferman
et al., 2010; Anuntaseree et al., 2012; Camfferman et al.,
2013; Chang et al., 2013). However, few studies have
addressed the quality of sleep in the adult eczema
population. Further, little is known about how different
patterns of sleep disturbance affect the overall health in
affected adults. Better understanding of the impact of adult
eczema on sleep patterns could lead to new treatment and
improve QOL. We hypothesized that adult eczema in the
United States is associated with fatigue and disturbance of
sleep patterns, which worsen overall health, independent of
allergic airway disease.
RESULTS
Prevalence of eczema and other atopic disorders
Data were collected on 34,613 adults, representing all age,
gender, and racial/ethnic groups. The US prevalence (95%
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confidence intervals (CIs)) of eczema in adults was 7.2% (6.9–
7.6%). Eight percent (7.6–8.4%) currently had asthma, 7.5%
(7.1–7.9%) had hay fever, 11.2% (10.8–11.7%) had respira-
tory allergies, and 3.9% (3.6–4.2%) had food or digestive
allergies.
Prevalence of eczema was significantly associated with
female sex (survey logistic regression; crude odds ratio (OR)
(95% CIs): 1.52 (1.36–1.70)) and post-high school education
(1.37 (1.13–1.66)) but inversely associated with African-
American race (0.82 (0.70–0.96)), Hispanic origin (0.73
(0.62–0.85)), household income of $75,000–99,999 (0.76
(0.61–0.95)), families with children and either a single parent
(0.79 (0.67–0.94)) or both parents living in the household
(0.76 (0.65–0.89)) compared with those that had no children,
and birthplace outside the United States (0.63 (0.54–0.73)).
Prevalence was not associated with age (Table 1). Class II and
III obesity, as defined by body mass index (BMI) of 35–39 and
X40, respectively, was also associated with eczema (class II:
1.31 (1.04–1.64); class III: 1.49 (1.18–1.88)).
Prevalence of fatigue and sleep disturbances
The 1-year prevalence of self-reported fatigue or lack of
energy for more than 3 days was 15.8% (15.0–16.0%).
Frequent excessive daytime sleepiness was described in
12.8% (12.3–13.2%), and 19.3% (18.8–19.9%) reported
regularly having insomnia or trouble sleeping. Among adults
who reported having regular insomnia, 43.6% (42.1–45.1%)
also reported fatigue, and 36.8% (35.3–38.2%) had daytime
sleepiness.
Prevalence of having more than 3 days of fatigue, regular
daytime sleepiness, and/or insomnia was associated with age
50–69 (1.42 (1.29–1.55)) and X70 years (1.59 (1.43–1.76)),
female sex (1.67 (1.57–1.78)), and lower household income
($0–34,999: 2.15 (1.95–2.36); $35,000–74,999: 1.55 (1.40–
1.71); $75,000–99,999: 1.19 (1.05–1.36)) and inversely asso-
ciated with African–American (0.80 (0.74–0.87)) and Asian
race (0.52 (0.45–0.60)), Hispanic origin (0.80 (0.74–0.87)),
single (0.81 (0.74–0.89)) or multiple (0.67 (0.62–0.73)) chil-
dren in the household, post-high school education (0.84
(0.76–0.92)), families that had children and either a single
parent (0.83 (0.76–0.90)) or both parents in the household
(0.60 (0.55–0.66)), and birthplace outside the United States
(0.62 (0.57–0.67)). There was a U-shaped distribution of
fatigue, daytime sleepiness, and/or insomnia associated with
BMI, such that both, being underweight (1.57 (1.24–1.98)) and
being obese (class I: 1.30 (1.19–1.42); class II: 1.90 (1.69–
2.15); class III: 2.59 (2.25–2.99)), were associated with a
higher prevalence of fatigue and sleep disturbance.
Association between eczema and sleep duration
History of eczema in the past year was associated with
significantly higher odds of both short (1.35 (1.20–1.51)) and
long (1.44 (1.19–1.74)) sleep duration (Table 2). These asso-
ciations remained significant in multivariate models that con-
trolled for the history of asthma, hay fever, respiratory allergy,
food or digestive allergy, age, sex, race, Spanish origin, house-
hold income, level of education, US birthplace, number of
children in the home, family structure, and BMI.
Association between eczema, fatigue, and sleep disturbance
Adults with eczema had a higher 1-year prevalence of fatigue
(5,580,472 people or 32.8% (30.4–35.2%)), regular daytime
sleepiness (4,430,186 people or 26.0% (23.8–28.3%)), and
insomnia (5,847,404 people or 34.4% (32.0–36.8%)) com-
pared with those without eczema (27.5% (26.9–28.1%);
Table 2). In particular, eczema was associated with higher
odds of fatigue (OR (95% CIs): 2.97 (2.65–3.34)), regular
daytime sleepiness (OR (95% CIs): 2.66 (2.34–3.01)), and
regular insomnia (OR (95% CIs): 2.36 (2.11–2.64)). These
associations remained significant in multivariate models that
included the above-mentioned atopic disorders, sociodemo-
graphics, and BMI, as well as sleep duration (Table 2).
Significant two-way interactions were found between symp-
toms of insomnia and fatigue/daytime sleepiness and between
insomnia and sleep duration. Therefore, contrast statements
were used to generate estimates for OR and 95% CIs at each
level of combination. Odds of eczema were higher in subjects
with either fatigue/daytime sleepiness (2.67 (2.28–3.13)) or
insomnia (1.96 (1.65–2.34)) and highest with both fatigue/
daytime sleepiness and insomnia (3.61 (3.15–4.12); Table 2).
Adults with insomnia had higher odds of eczema for all sleep
durations (3–6 hours: 2.38 (2.05–2.76); 7–8 hours: 2.40 (2.02–
2.85); 9–14 hours: 3.72 (2.73–5.05)). These interactions
remained significant in multivariate models. In contrast, adults
without insomnia did not have significant interactions with
sleep duration as predictors of eczema.
There were no significant differences of association between
eczema, asthma and/or hay fever, and sleep disturbance in
obese (class I–III) versus normal weight adults (data not
shown).
Association between eczema, fatigue, sleep disturbance, and
overall health status
In univariate models, eczema (OR (95% CIs): 1.98 (1.74–
2.26)), fatigue (6.21 (5.70–6.76)), daytime sleepiness (4.71
(4.29–5.16)), and insomnia (3.99 (3.68–4.33)) were all signifi-
cant predictors of having only fair/poor overall health. How-
ever, there were significant two-way interactions between
eczema and fatigue and sleep disturbances. In models of
interaction between eczema and fatigue, eczema alone was
associated with fair/poor health (OR (95% CIs): 1.29 (1.07–
1.56)), whereas fatigue without eczema was associated with
higher odds of fair/poor health (OR (95% CIs): 5.93 (5.42–
6.50)); those with both eczema and fatigue had even higher
odds of fair/poor health (OR (95% CIs): 8.63 (7.15–10.43);
Table 3).
Similarly, in models of interaction between eczema and
regular daytime sleepiness or insomnia, eczema alone was
consistently associated with fair/poor health; regular daytime
sleepiness or insomnia without eczema had even higher odds
of fair/poor health; and both regular daytime sleepiness or
insomnia and eczema had the highest odds of fair/poor health.
Associations between eczema, sleep disturbances, and number
of sick days and doctor visits
Significant two-way interactions were found between eczema
and sleep disturbances as predictors of the number of missed
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Table 1. Determinants of eczema and sleep problems in adults (n¼ 34,613)
Variable—no. (%)
Eczema Fatigue, daytime sleepiness, or insomnia
% Prev (95% CI) Crude OR (95% CI) P-value % Prev (95% CI) Crude OR (95% CI) P-value
Age (years)
18–29 6.6 (5.8–7.4) 1.00 — 25.6 (24.1–27.0) 1.00 —
30–49 7.4 (6.7–8.0) 1.12 (0.96–1.31) 0.14 26.2 (25.2–27.2) 1.03 (0.94–1.14) 0.47
50–69 7.6 (7.0–8.3) 1.17 (1.00–1.37) 0.05 32.7 (31.6–33.8) 1.42 (1.29–1.55) o0.0001
X70 6.9 (6.0–7.8) 1.05 (0.87–1.27) 0.59 35.3 (33.6–37.0) 1.59 (1.43–1.76) o0.0001
Sex
Male 5.8 (5.3–6.3) 1.00 — 23.8 (22.9–24.6) 1.00 —
Female 8.6 (8.0–9.1) 1.52 (1.36–1.70) o0.0001 34.3 (33.4–35.2) 1.67 (1.57–1.78) o0.0001
Race
Caucasian 7.4 (7.0–7.8) 1.00 — 30.4 (29.7–31.1) 1.00 —
African American 6.1 (5.3–7.0) 0.82 (0.70–0.96) 0.01 25.9 (24.4–27.4) 0.80 (0.74–0.87) o0.0001
American Indian 8.2 (5.0–11.4) 1.12 (0.73–1.72) 0.59 34.3 (28.3–40.2) 1.20 (0.92–1.56) 0.19
Asian 6.6 (5.3–8.0) 0.89 (0.71–1.11) 0.31 18.4 (16.3–20.5) 0.52 (0.45–0.60) o0.0001
Multiracial/other 13.3 (6.7–20.0) 1.93 (1.08–3.44) 0.03 29.3 (20.7–37.9) 0.95 (0.63–1.44) 0.81
Hispanic origin
No 7.5 (7.1–7.9) 1.00 — 29.9 (29.2–30.6) 1.00 —
Yes 5.6 (4.8–6.3) 0.73 (0.62–0.85) o0.0001 25.5 (24.0–26.9) 0.80 (0.74–0.87) o0.0001
Household income ( $1,000)
0–34 7.3 (6.8–7.9) 0.97 (0.83–1.12) 0.65 36.8 (35.8–37.8) 2.15 (1.95–2.36) o0.0001
35–74 7.8 (7.1–8.5) 1.03 (0.88–1.21) 0.72 29.6 (28.4–30.7) 1.55 (1.40–1.71) o0.0001
75–99 5.9 (4.9–6.8) 0.76 (0.61–0.95) 0.01 24.5 (22.6–26.3) 1.19 (1.05–1.36) 0.008
X100 7.6 (6.7–8.5) 1.00 — 21.4 (20.0–22.7) 1.00 —
Children in household
None 7.8 (7.3–8.2) 1.00 — 31.4 (30.7–32.2) 1.00 —
Single 6.3 (5.4–7.2) 0.80 (0.68–0.94) 0.008 27.2 (25.5–28.9) 0.81 (0.74–0.89) o0.0001
Multiple 6.1 (5.4–6.9) 0.78 (0.67–0.90) 0.0009 23.5 (22.2–24.8) 0.67 (0.62–0.73) o0.0001
Highest level of household education
oHigh school 5.8 (4.8–6.7) 1.00 — 33.1 (31.2–35.0) 1.00 —
High school or GED 5.7 (5.0–6.3) 0.98 (0.79–1.22) 0.85 31.4 (30.0–32.7) 0.92 (0.83–1.03) 0.15
4High school 7.7 (7.2–8.2) 1.37 (1.13–1.66) 0.001 29.2 (28.4–30.1) 0.84 (0.76–0.92) 0.0002
Family structure
No children 7.8 (7.3–8.2) 1.00 — 31.4 (30.7–32.2) 1.00 —
Both parents 6.3 (5.4–7.2) 0.76 (0.65–0.89) 0.0004 21.6 (20.3–23.0) 0.60 (0.55–0.66) o0.0001
Single parent 7.5 (4.6–10.4) 0.79 (0.67–0.94) 0.007 27.5 (25.8–29.1) 0.83 (0.76–0.90) o0.0001
Other adult, no parents 6.0 (5.2–6.8) 0.96 (0.63–1.46) 0.84 34.7 (29.4–40.0) 1.16 (0.92–1.47) 0.22
Birthplace in the United States
No 5.0 (4.3–5.6) 0.63 (0.54–0.73) o0.0001 21.6 (20.3–22.8) 0.62 (0.57–0.67) o0.0001
Yes 7.7 (7.3–8.1) 1.00 — 30.8 (30.1–31.5) 1.00 —
Body mass index
o18.5 7.8 (4.9–10.6) 1.11 (0.74–1.67) 0.62 35.6 (30.4–40.9) 1.57 (1.24–1.98) 0.0002
18.5–24.9 7.1 (6.5–7.7) 1.00 — 26.1 (25.1–27.1) 1.00 —
25–29.9 6.6 (6.0–7.2) 0.93 (0.81–1.06) 0.29 26.2 (25.2–27.3) 1.01 (0.93–1.09) 0.87
30–34.9 7.3 (6.4–8.2) 1.04 (0.89–1.22) 0.63 31.4 (29.9–32.9) 1.30 (1.19–1.42) o0.0001
35–39.9 9.0 (7.3–10.7) 1.31 (1.04–1.64) 0.02 40.2 (37.6–42.8) 1.90 (1.69–2.15) o0.0001
X40 10.1 (8.2–12.1) 1.49 (1.18–1.88) 0.0009 47.8 (44.5–51.1) 2.59 (2.25–2.99) o0.0001
Abbreviations: CI, confidence interval; GED, graduate equivalent degree; OR, odds ratio; Prev, prevalence.
Refusal to answer a particular question or response of ‘‘don’t know’’ occurred for the questions pertaining to eczema in 25 (0.07%), fatigue in 20 (0.05%),
daytime sleepiness in 14 (0.04%), insomnia in 9 (0.02%), current asthma in 37 (0.1%), hay fever in 25 (0.07%), respiratory allergies in 48 (0.1%) and digestive
allergies in 37 (0.1%), age in 0 (0.0%), sex in 0 (0.0%), race in 0 (0.0%), Hispanic/Spanish origin in 0 (0.0%), household income in 1,928 (5.6%), highest level
of education in the household in 69 (0.2%), US birthplace in 10 (0.03%), number of children in home in 0 (0.0%), family structure in 4 (0.01%), and body mass
index in 1,361 (3.9%), respectively.
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Table 2. Eczema as a predictor of sleep duration, fatigue, daytime sleepiness, and insomnia in adults (n¼ 34,613)
Variable
No eczema Eczema
% Prev (95% CI)1 % Prev (95% CI)2 OR (95% CI) P-value aOR (95% CI) P-value
Sleep duration (h)
Short: 3–6 28.9 (28.2–29.5) 34.3 (31.9–36.7) 1.35 (1.20–1.51) o0.0001 1.30 (1.14–1.79) 0.0001
Average: 7–8 62.8 (62.1–63.5) 55.2 (52.6–57.7) 1.00 (ref) — 1.00 (ref) —
Long: 9–14 8.3 (7.9–8.7) 10.5 (8.8–12.2) 1.44 (1.19–1.74) 0.0002 1.43 (1.14–1.79) 0.002
Fatigue
No 85.9 (85.4–86.4) 67.2 (64.8–69.6) 1.00 — 1.00 —
Yes 14.1 (13.6–14.6) 32.8 (30.4–35.2) 2.97 (2.65–3.34) o0.0001 2.23 (1.93–2.58) o0.0001
Daytime sleepiness
No 88.3 (87.8–88.7) 74.0 (71.7–76.2) 1.00 — 1.00 —
Yes 11.7 (11.3–12.2) 26.0 (23.8–28.3) 2.66 (2.34–3.01) o0.0001 2.04 (1.75–2.38) o0.0001
Insomnia overall
No 81.8 (81.3–82.4) 65.6 (63.2–68.0) 1.00 — 1.00 —
Yes 18.2 (17.6–18.7) 34.4 (32.0–36.8) 2.36 (2.11–2.64) o0.0001 1.83 (1.59–2.12) o0.0001
Insomnia Fatigue
No No 75.3 (74.7–75.9) 52.7 (50.1–55.3) 1.00 — 1.00 —
No Yes 6.6 (6.2–6.9) 12.9 (11.1–14.7) 2.80 (2.34–3.35) o0.0001 2.22 (1.80–2.74) o0.0001
Yes No 10.6 (10.2–11.0) 14.5 (12.7–16.3) 1.94 (1.66–2.28) o0.0001 1.65 (1.35–2.00) o0.0001
Yes Yes 7.5 (7.1–7.9) 19.9 (17.9–21.9) 3.78 (3.28–4.35) o0.0001 2.74 (2.28–3.29) o0.0001
Insomnia Daytime sleepiness
No No 76.5 (76.0–77.1) 55.5 (53.0–58.1) 1.00 — 1.00 —
No Yes 5.3 (5.0–5.6) 10.1 (8.5–11.8) 2.63 (2.16–3.21) o0.0001 2.22 (1.77–2.78) o0.0001
Yes No 11.7 (11.3–12.2) 18.4 (16.5–20.4) 2.17 (1.88–2.50) o0.0001 1.78 (1.48–2.13) o0.0001
Yes Yes 6.4 (6.1–6.8) 15.9 (14.2–17.7) 3.42 (2.95–3.98) o0.0001 2.47 (2.04–2.99) o0.0001
Insomnia Sleep duration (h)
No 3–6 23.3 (22.6–24.0) 25.1 (22.4–27.9) 1.14 (0.97–1.32) 0.11 1.18 (0.98–1.41) 0.07
No 7–8 68.2 (67.5–68.9) 64.9 (61.8–68.0) 1.00 — 1.00 —
No 9–14 8.5 (8.1–9.0) 10.0 (8.0–12.0) 1.23 (0.97–1.56) 0.08 1.30 (0.99–1.71) 0.06
Yes 3–6 54.5 (52.9–56.1) 51.9 (47.6–56.1) 2.38 (2.05–2.76) o0.0001 1.94 (1.63–2.32) o0.0001
Yes 7–8 38.1 (36.5–39.7) 36.6 (32.5–40.8) 2.40 (2.02–2.85) o0.0001 1.93 (1.57–2.37) o0.0001
Yes 9–14 7.4 (6.5–8.3) 11.5 (8.6–14.4) 3.86 (2.83–5.26) o0.0001 3.07 (2.08–4.51) o0.0001
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio; Prev, prevalence.
Binary survey logistic regression models were constructed with sleep duration (3–6, 7–8, and 9–14 hours) and 1-year history of more than 3 days with fatigue or
tiredness and regular daytime sleepiness and insomnia as the independent variables and 1-year history of eczema as the dependent variable. OR and 95% CIs
were estimated. Multivariate logistic regression models were constructed that included current asthma, hay fever, respiratory and digestive allergies, age, race,
Hispanic/Spanish origin, household income, highest level of education in the household, US birthplace, number of children in home, family structure, and
body mass index. Models of fatigue, daytime sleepiness, and insomnia also included sleep duration as a covariate. A significant two-way interaction was found
between insomnia and fatigue, daytime sleepiness, and sleep duration (Po0.0001). Contrast statements were used to estimate various combinations of
insomnia, fatigue, daytime sleepiness, and sleep duration.
Refusal to answer a particular question or response of ‘‘don’t know’’ occurred for the questions pertaining to eczema in 25 (0.07%), sleep duration in 497
(1.3%), fatigue in 20 (0.05%), daytime sleepiness in 14 (0.04%), insomnia in 9 (0.02%), current asthma in 37 (0.1%), hay fever in 25 (0.07%), respiratory
allergies in 48 (0.1%) and digestive allergies in 37 (0.1%), age in 0 (0.0%), sex in 0 (0.0%), race in 0 (0.0%), Hispanic/Spanish origin in 0 (0.0%), household
income in 1,928 (5.6%), highest level of education in the household in 69 (0.2%), US birthplace in 10 (0.03%), number of children in home in 0 (0.0%), family
structure in 4 (0.01%), and body mass index in 1,361 (3.9%), respectively.
1Data are presented as the percent prevalence of sleep duration and/or disturbance in subjects with no history of eczema.
2Data are presented as the percent prevalence of sleep duration and/or disturbance in subjects with a history of eczema.
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workdays, days in bed, and doctor visits. Adults who had
eczema as well as fatigue, daytime sleepiness, and/or insom-
nia had even higher numbers of missed workdays and days in
bed than those with either eczema or fatigue/sleep distur-
bances (general linear models, Po0.0001 for all; Figure 1a–f).
In contrast, adults with eczema and insomnia had a higher
number of doctor visits than those with either eczema or
insomnia (Po0.0001), but a similar number to those with
fatigue or daytime sleepiness and no eczema (PX0.66;
Figure 1g–i). Similar results were also found with the
Wilcoxon rank sum test and Poisson regression models (data
not shown).
We tested whether the association between eczema and
overall health status is mediated by fatigue and/or sleep
disturbance using three different approaches. All approaches
indicated there was significant mediation (the Sobel test
(95% CIs): 0.042 (0.038–0.046), Po0.0001; bootstrapping
approach, indirect effects OR (95% CIs): 1.10 (1.09–1.11)),
although only partial mediation (b(yx,m)¼0.02, P¼ 0.003;
R2¼0.002). Similarly, partial mediation was found for the
number of missed workdays (the Sobel test (95% CIs): 0.02
(0.015–0.027), Po0.0001; bootstrapping approach, indirect
effects OR (95% CIs): 1.05 (1.03–1.07); b(yx,m)¼ 0.06,
P¼0.01; R2¼ 0.0003) and doctor visits (the Sobel test (95%
CIs): 0.28 (0.23–0.33), Po0.0001; bootstrapping approach,
indirect effects OR (95% CIs): 1.92 (1.70–2.19); b(yx,m)¼
1.02, Po0.0001; R2¼0.003).
Latent class analysis of fatigue, sleep disturbance, and allergic
disorders
LCA was used to identify patterns of fatigue, sleep disturbances,
and allergic disorders. The best-fit model had five classes based
on minimal Bayesian information criteria, corrected Akaike
information criteria, and adjusted Bayesian information criteria
(Supplementary Table 2 online). Conditional probabilities of
having fatigue, sleep disturbance, or allergic disease in each
class are plotted in Figure 2. Two classes had high probabilities
of sleep disturbance (classes 3 and 4). Class 4 had high
probabilities of eczema, asthma, hay fever, and food allergy,
whereas class 3 had low probabilities of these disorders. Class 1
had an intermediate probability of insomnia but not fatigue or
sleepiness; this group also had an intermediate probability of
eczema. Class 2 included those with a high probability of hay
fever and respiratory allergies but low probability of fatigue and
sleep disturbances. Finally, class 5 included those with a low
probability of fatigue, sleep disturbance, and allergic disease.
Table 3. Association between eczema and overall health status is related to sleep disturbance in adults (n¼ 34,613)
Variable Eczema
Poor/fair vs. excellent/very good/good health
% Poor/fair (95% CI) OR (95% CI) P-value aOR (95% CI) P-value
Fatigue
No No 8.5 (8.1–8.9) 1.00 — 1.00 —
No Yes 10.7 (9.0–12.5) 1.29 (1.07–1.56) 0.009 1.41 (1.13–1.76) 0.002
Yes No 35.6 (33.8–37.3) 5.93 (5.42–6.50) o0.0001 5.23 (4.68–5.85) o0.0001
Yes Yes 44.5 (40.0–49.0) 8.63 (7.15–10.43) o0.0001 7.53 (5.97–9.49) o0.0001
Sleepiness
No No 9.6 (9.2–10.0) 1.00 — 1.00 —
No Yes 14.7 (12.7–16.8) 1.62 (1.37–1.92) o0.0001 1.71 (1.40–2.09) o0.0001
Yes No 32.7 (30.8–34.6) 4.57 (4.15–5.05) o0.0001 4.00 (3.55–4.50) o0.0001
Yes Yes 41.9 (36.9–46.9) 6.78 (5.49–8.36) o0.0001 5.23 (4.08–6.71) o0.0001
Insomnia
No No 9.0 (8.6–9.4) 1.00 — 1.00 —
No Yes 12.9 (10.6–15.2) 1.50 (1.21–1.85) 0.0002 1.58 (1.26–1.99) o0.0001
Yes No 27.4 (25.9–28.0) 3.81 (3.49–4.16) o0.0001 3.27 (2.95–3.62) o0.0001
Yes Yes 38.8 (34.8–42.9) 6.43 (5.37–7.68) o0.0001 5.18 (4.12–6.51) o0.0001
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.
Binary survey logistic regression models were constructed with overall health status as the dependent variable (fair/poor vs. excellent/very/good) and 1-year
history of eczema and fatigue, daytime sleepiness, and/or insomnia as the independent variable. Significant interactions found between history of eczema and
sleep disturbances. Contrast statements were used to estimate OR and 95% CIs at each level of interaction. Multivariate logistic regression models were
constructed that included current asthma, hay fever, respiratory and digestive allergies, age, race, Hispanic/Spanish origin, household income, highest level of
education in the household, US birthplace, number of children in home, family structure, body mass index, and sleep duration.
Refusal to answer a particular question or response of ‘‘don’t know’’ occurred for the questions pertaining to eczema in 25 (0.07%), sleep duration in 497
(1.3%), fatigue in 20 (0.05%), daytime sleepiness in 14 (0.04%), insomnia in 9 (0.02%), overall health in 0 (0.0%), current asthma in 37 (0.1%), hay fever in 25
(0.07%), respiratory allergies in 48 (0.1%) and digestive allergies in 37 (0.1%), age in 0 (0.0%), sex in 0 (0.0%), race in 0 (0.0%), Hispanic/Spanish origin in 0
(0.0%), household income in 1,928 (5.6%), highest level of education in the household in 69 (0.2%), US birthplace in 10 (0.03%), number of children in home
in 0 (0.0%), family structure in 4 (0.01%), and body mass index in 1,361 (3.9%), respectively.
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DISCUSSION
In the present study, we demonstrate that eczema in adults is
associated with both short and long sleep durations. Short
duration is likely due to difficulty falling asleep and premature
awakening secondary to itch, whereas long duration is likely
due to poor sleep efficiency, excessive fatigue, and sleepiness
and perhaps the use of sedating antihistamines. Even after
controlling for sleep duration, other atopic diseases, and
sociodemographic factors, eczema was associated with fati-
gue, daytime sleepiness, and insomnia. In particular, adults
with insomnia as well fatigue and/or daytime sleepiness had
the highest odds of eczema. Adults with eczema were more
likely to have fair/poor overall health, even without fatigue or
sleep disturbances. However, the presence of fatigue or sleep
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Figure 1. Association between eczema, sleep disturbance, and number of sick days, days in bed, and doctor visits. General linear models were constructed with
number of sick days (a–c), days in bed (d–f), and doctor visits (g–i) as the dependent variables using a normal link function. The dependent variables were eczema,
as well as fatigue (left column), daytime sleepiness (middle column), or insomnia (right column), and a two-way interaction term between them. Post hoc analyses
were conducted of differences among the levels of one factor at a fixed level of the other factor. Least-square means (95% confidence intervals (CIs)) are plotted for
each combination of factors included in the interaction effects. In addition, b values (95% CIs) for comparisons between each group and those without eczema or
sleep disturbance are presented as text.
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disturbance and eczema led to significantly higher rates of
self-reported fair/poor health, as well as higher numbers of
missed workdays, days in bed, and doctor visits. The associa-
tions between eczema and poorer health outcomes were only
partially mediated by fatigue and/or sleep disturbance, sug-
gesting that there are additional factors at play. Finally, there
were two distinct groups of subjects that had sleep disturbance
with eczema: one with other allergic disease who had higher
probabilities of insomnia, fatigue, and daytime sleepiness and
the other with a higher probability of insomnia alone. Of note,
there were other latent classes observed with similar prob-
abilities of eczema and low probabilities of fatigue, insomnia,
and/or sleepiness, indicating there are subsets of eczema
without major sleep disturbances. Together, the results of this
study suggest that adults with eczema have high rates of
fatigue and sleep disturbances, which severely impact on
overall health and increase health care utilization. With
almost 9 million US adults with eczema reporting fatigue or
sleep disturbance, our study demonstrates the considerable
public health burden of eczema. A previous study of child-
hood atopic dermatitis (AD) found that having more severe
disease was associated with increased health care utilization,
including seeing a specialist and using more health-related
services (Silverberg and Simpson, 2013). The results of the
present study suggest that fatigue and sleep disturbances are
major drivers of lost workdays and increased health care
utilization and weigh heavily on the public health burden of
eczema. It would therefore be prudent to improve our
understanding of sleep disturbance in eczema and why
some eczema patients are particularly affected by sleep
problems, whereas others are not. Ultimately, this will lead
to targeted interventions for prevention and treatment and
improved care of eczema.
Previous smaller-scale studies also found high rates of sleep
disturbances among adults with eczema (Bender et al., 2003;
Zuberbier et al., 2006; Hanifin et al., 2007; Bender et al.,
2008; Torrelo et al., 2012). A case-control study of 14 eczema
patients and 14 control patients without skin disease assessed
sleep impairment using the Pittsburgh sleep quality index and
actigraphy (Bender et al., 2003). Questionnaires revealed
lower sleep quality, more awakening, and daytime dysfunc-
tion among eczema patients. Similarly, actigraphic assessment
revealed that eczema patients slept less, awoke more often,
and spent more time awake during waking episodes, with
resultant lower overall sleep efficiency (Bender et al., 2003).
Another study administered questionnaires, actigraphy, and
polysomnography to 20 adult eczema patients and found that
greater disease severity was associated with poorer sleep
(Bender et al., 2008). A multicenter questionnaire–based study
from the International Study of Life with Atopic Eczema,
including 1,098 adults, found that a typical AD flare disrupts
the sleep of patients for an average of 8.4 nights per flare,
which extrapolated to B81 days per year per patient
(Zuberbier et al., 2006).
An important limitation of the above-mentioned studies is
the lack of control for comorbid asthma and rhinoconjuncti-
vitis, which are common confounding factors in adults with
eczema (Silverberg and Hanifin, 2013) and can independently
cause sleep disturbances. Approximately 40% of asthma
patients experience night-time awakenings every night
(Turner-Warwick, 1988), leading to shortened sleep duration
and increased daytime sleepiness (Dales et al., 1992;
Fitzpatrick et al., 1993; Janson et al., 1996; Vir et al., 1997;
Craig et al., 2004; Leger et al., 2006; Mastronarde et al., 2008).
In addition, the prevalence of early morning awakenings and
difficulty inducing sleep was twice as high, and the prevalence
of daytime sleepiness 50% higher, in European asthmatic
adults compared with non-asthmatics (Janson et al., 1996).
Similarly, allergic rhinitis sufferers experience interruption of
the sleep cycle leading to increased daytime somnolence and
decreased QOL, attributed to nasal obstruction and linked to
increased night-time microarousals (Lavie et al., 1981; Craig
et al., 2004; Leger et al., 2006; Bender and Leung, 2005; Leger
et al., 2006). We now demonstrate an association between
eczema, fatigue, and sleep disturbances, even after controlling
for the history of respiratory allergies, as well as for food
and digestive allergies and other potentially confounding
sociodemographic factors. Moreover, LCA models revealed a
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Figure 2. Conditional probability plot for sleep disturbance, eczema, and allergic disease within latent classes. Latent class analysis (LCA) was used to examine
patterns of binary variables of sleep disturbance and the occurrence of eczema, asthma, hay fever, and respiratory and/or food (digestive (Dig)) allergy. LCA used
the observed binary data to identify homogeneous patterns, i.e., n¼ 5 latent classes. Conditional probabilities were estimated using maximum likelihood to
characterize the latent classes. Conditional probability plots are presented, where probabilities closer to 0 or 1 indicate lower or higher chances, respectively.
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latent class of adults with eczema that had higher probability
of insomnia even in the absence of other allergic disorders.
Allergic airway disorders that often accompany eczema,
such as asthma and hay fever, are associated with obstructive
sleep apnea (OSA) and its sequelae. A study of OSA syndrome
found a higher risk of perennial allergic rhinitis (Canova
et al., 2004). Similarly, our study found significant associa-
tions between obesity and each of the sleep disturbances
(consistent with OSA) in adults with asthma and hay fever.
Yet, there were no such associations between obesity, sleep
disturbances, and eczema, suggesting that the sleep
disturbances in adult eczema patients were not due to OSA
or comorbid airway disease. Rather, pruritus is likely the major
contributor to sleep disturbance in eczema. Further studies are
needed to identify the specific patterns of sleep disturbance in
eczema and distinguish them from those found in atopic
airway disorders.
Our results also confirm past observations in the United
States (Karacan et al., 1976) and Japan (Doi et al., 2000)
showing the association of sleep disturbance with female
gender, older age, and lower household income. The lower
prevalences of sleep disturbances among African-Americans,
Asians, and Hispanics with eczema are consistent with
previously described racial/ethnic differences in sleep
disturbances regardless of eczema (Ruiter et al., 2011;
Ralls and Grigg-Damberger, 2012; Chapman et al., 2013;
Grandner et al., 2013; Jackson et al., 2013; Knutson, 2013;
Pranathiageswaran et al., 2013). They may be related to
differential self-reporting and household income, and reflect
socioeconomic differences of adult sleep patterns, including
differences in sleep behavior and duration, social pressures
and psychosocial stress, poor environmental conditions, noise,
air, and light pollution, more nightshift work, etc. Future
studies with objective measurements of sleep disturbance are
needed to verify these associations.
Growing evidence suggests an association of eczema with
obesity, including the results of our study. Obesity has
previously been associated with increased prevalence and
severity of eczema and higher prevalence of atopic asthma in
2,090 adults agedX19 (Silverberg et al., 2012). Another study
associated prolonged obesity (42.5 years) in early childhood
and increased odds and severity of eczema (Silverberg et al.,
2011), suggesting that obesity and its chronic pro-inflam-
matory effects (Jin and Flavell, 2013) may be a modifiable risk
factor for eczema. In the present study, obesity was also
associated with higher prevalence of eczema but not with
greater sleep disturbances in eczema.
Eczema is known to have a significant and negative impact
on health-related QOL (Bender et al., 2003; Beattie and Lewis-
Jones, 2006; Ricci et al., 2007; Hon et al., 2008; Beikert et al.,
2014), and our study supports this notion by demonstrating that
sleep disturbance is a major driver of poor overall health status,
lost workdays, and increased health care utilization. In 384
adult eczema patients, sleep disturbance was strongly
associated with decreased QOL using Dermatology Life
Quality Index (Beikert et al., 2014). In childhood eczema,
sleep disturbance was the second highest scoring item,
alongside itching (Hon et al., 2008). Other studies in
children similarly demonstrate that sleep disturbance is
among the top contributing factors to reduced QOL (Beattie
and Lewis-Jones, 2006; Ricci et al., 2007). Together, these
studies suggest that interventions targeting sleep disturbance
are of utmost importance and likely to improve the overall
health and QOL of adults and children with eczema.
The present study found the 1-year prevalence of adult
eczema to be 7.2%, which is lower than the 10.2% pre-
valence recently demonstrated by Silverberg and Hanifin
(2013). There are a number of differences between the
questions used to measure eczema prevalence in these
studies. The question used in the study of Silverberg and
Hanifin (a) did not specify health care diagnosis of eczema
and (b) assessed for ‘‘eczema, dermatitis, or red inflamed
rash’’, which is less specific but more sensitive than the
question used in the present study. Of note, many adult
eczema patients either underutilize or do not utilize health
care for their eczema (data not shown). Thus, the health care-
diagnosed eczema outcome used in the present study may
introduce a selection bias toward those who have higher
household income and greater access to health care and are
more likely to utilize health care for their eczema. This may
explain why the previously demonstrated inverse association
between eczema prevalence and household income was not
found in the present study. It is therefore possible that the
present study actually underestimates the prevalence of sleep
disturbances in US adults with eczema. Regardless, we
believe that the eczema question used in this study is
sufficiently sensitive and specific to examine the burden of
sleep disturbances in adult eczema.
The mechanisms underlying the association between
eczema and sleep disturbance are not fully understood. The
itch-scratch cycle of eczema interferes with initiation and
maintenance of sleep (Camfferman et al., 2010). Actigraphy
and infrared video evidence reveals fragmented sleep with
increased scratch time and restless nocturnal movement in
both adults and children with eczema (Camfferman et al.,
2010). In addition, evidence for circadian rhythm–induced
modification of itch exists, as studies have shown greater
transepidermal water loss at night time along with decreased
cortisol secretion (Gupta and Gupta, 2013). Both processes
may lead to increased night time itch and fragmented sleep.
Inflammatory cytokines implicated in sleep regulation are also
elevated in patients with allergy (Bender and Leung, 2005).
However, patients with eczema, even when in clinical
remission, exhibit more sleep impairment than do healthy
patients (Reuveni et al., 1999), suggesting a more complex
etiology beyond itch and inflammatory pathway activation. In
a study of five children with eczema, regular antihistamine use
had no effect on sleep latency, total sleep time, or other sleep
parameters, determined by polysomnography (Camfferman
et al., 2013). However, the role of learned abnormal
sleeping patterns or medication use (e.g., antihistamines or
corticosteroids, which may interfere with sleep-wake
regulation) deserves exploration in larger-scale studies.
This study has several strengths, including having prospec-
tive data collection, US population-based, and having a very
large, randomly sampled and diverse sample. In addition, the
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study had sufficient numbers for subset analyses and was
controlled for a large number of potential confounding factors
using logistic regression. The use of latent class analysis (LCA)
allowed for identification of two distinct patterns of sleep
disturbance in adult eczema. The random sampling, large
sample size across all states, with representation of a host of
racial and ethnic groups and complex weighting indicate that
the results are likely generalizable to the entire US population.
However, this study has potential limitations. Eczema history
was based on a self-report of health care diagnosis and neither
assessed clinically nor verified with any diagnostic testing. The
specific question used in this study has not been previously
validated; however, self-report of eczema using other instru-
ments has been validated and found to have good correlation
with clinical exam (Susitaival et al., 1995; Flohr et al., 2009).
Moreover, the waxing and waning course and more variable
presentation of adult eczema argue in favor of a broader
question related to the history of eczema in the past 12
months. Nevertheless, there may be more than one type of
eczema in adults (Abuabara and Margolis, 2013) that are
detected by the question used in this study, including irritant,
allergic contact, and xerotic dermatitis. We do not consider
this to be a limitation because adult eczema often has a
variable phenotype compared with childhood eczema and
may present with overlapping atopic, irritant, and/or allergic
contact dermatitis, rather than flexural eczema alone (Katsarou
and Armenaka, 2011; Silverberg, 2014). Previous studies
found a strong correlation between self-report of fatigue and
sleepiness and objective measures of sleep disturbance: i.e.,
actigraphy and polysomnography (Bender et al., 2008; Braley
et al., 2012). Further, self-reported measures of sleep
disturbance have been the mainstay of epidemiologic study
of sleep in cardiovascular disease (Shankar et al., 2010;
Westerlund et al., 2013), diabetes (Plantinga et al., 2012),
chronic kidney disease (Plantinga et al., 2011), etc. Family
history of eczema may be an important confounding factor but
was not assessed in National health interview survey (NHIS).
The accuracy of self-reported family history by adults with
eczema has not previously been studied and, based on the
authors’ clinical experience, is likely not very reliable. Finally,
the cross-sectional nature of the study does not allow for the
determination of causality of the association between eczema
and sleep. That is, eczema may cause sleep impairment or
perhaps underlying sleep disorders trigger eczema in
predisposed individuals. Future longitudinal studies with
objective measures of sleep disturbance are needed to verify
these associations.
In conclusion, adult eczema is associated with altered sleep
duration, fatigue, and sleep disturbances, including daytime
sleepiness and insomnia. Although adults with eczema were
more likely to report fair/poor health, the presence of sleep
disturbances in combination with eczema significantly
increased the rates of fair/poor health. This study suggests that
sleep disturbances weigh heavily on adults with eczema and
that treatments targeting sleep loss are likely to improve the
overall health of eczema patients. Future studies are warranted
to better characterize sleep loss in eczema and develop
strategies for treatment and prevention.
MATERIALS AND METHODS
National health interview survey
After approval by Northwestern University’s institutional review
board, data were assessed using 2012 NHIS, a database collected
by the National Center for Health Statistics and the principal source of
health information on US noninstitutionalized civilians. Waiver of
informed consent was obtained by the National Center for Health
Statistics, as the survey posed minimal risk and respondents were not
identifiable by the recorded data. The survey included a separate
questionnaire about adult health to estimate the prevalence of
physical, emotional, and behavioral health issues. The survey was
administered in-person to selected households by the Bureau of the
Census using B400 trained interviewers with computer-assisted
personal interviewing in English and Spanish. Using data from the
US Census Bureau, sample weights were created that factored age,
sex, race, ethnicity, household size, and educational attainment of the
most educated household member using a multi-stage area prob-
ability sampling design by NHIS. These sample weights are needed to
provide nationally representative prevalence estimates for each state’s
population of noninstitutionalized adults. All frequency data are
presented as raw values, whereas prevalence estimates presented
reflect this complex weighting. Questions used in the survey pertain-
ing to history of eczema, sleep problems, and overall health are listed
in Supplementary Table 1 online.
All data processing and statistical analyses were performed in SAS
version 9.3. Outlier detection was performed for sleep duration
revealing that responses ofX15 hours duration were outliers. Models
that incorporated sleep duration were tested with and without the
exclusion of outliers, and no significant differences were found.
Therefore, we only present models that excluded outliers. Bivariate
and multivariate analyses of survey responses were performed
using SURVEY procedures. Bivariate associations were tested with
Rao-Scott w2 tests. Multivariate logistic regression models were
constructed for fatigue, daytime sleepiness, and insomnia (binary
outcomes) using two different approaches. First, we included all
significant predictors from bivariate analyses in the models. Two- and
three-way interaction terms between other covariates were also
tested. Our a priori hypothesis was that adult eczema is associated
with specific patterns of insomnia with sleep duration, fatigue, and
sleepiness. Therefore, models were constructed that tested interaction
terms between insomnia and either sleep duration, fatigue, or daytime
sleepiness. We used stepwise and backward selection for multivariate
logistic regression models to determine whether eczema would be
selected consistently as a predictor and identify other significant
predictors of sleep problems. Adjusted ORs (aORs) and 95% CIs were
determined.
Multivariate logistic regression models were also constructed with
personal health status as the dependent variable. Personal health
status was modeled as the binary dependent variable. This approach
was used over ordinal logistic regressions because the data did not
meet the proportional odds assumption (Score test, Po0.01). Our a
priori hypothesis was that adults with eczema, fatigue, and sleep
disturbances have worse overall health than those with eczema
alone. Therefore, models were constructed that tested interaction
terms between eczema and sleep problems. Significant predictors
from bivariate analyses were also included in the models.
Number of sick days, days in bed, and doctor visits were modeled
using generalized linear models with a normal (linear regression) and
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log (poisson regression) link function in SAS PROC GLIMMIX. The
independent variables were history of eczema, as well as fatigue,
daytime sleepiness, or insomnia and a two-way interaction term
between them. Post hoc analyses were conducted of differences
among the levels of one factor at a fixed level of the other factor.
Least-square means and aORs (95% CIs) were estimated for each
combination of factors included in the interaction effects.
Two- and three-way interactions between other covariates were
tested and included in the above models if P-value o0.01 and
modification of estimates by 420%. The best models were selected
using the Bayesian information criterion, which penalizes for extra
parameters and takes into account the large sample size. To test
whether any associations between eczema and poor personal health
status, lost workdays, and health care utilization were mediated by
fatigue and/or sleep disturbance (composite binary variable), media-
tion was tested using the approaches of Baron and Kenny, the Sobel
test, and the bootstrap method described by Preacher and Hayes
(n¼ 5,000 bootstrapping samples; Preacher and Hayes, 2008).
Complete data analysis was performed, i.e., subjects with missing
data were excluded.
LCA was performed in SAS as previously described (Yang et al.,
2012; Supplementary Methods online).
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